Clinical Trial News and Research

RSS

FDA forms new internal task force to support development of new antibacterial drugs

The U.S. Food and Drug Administration today announced the formation of an internal task force that will support the development of new antibacterial drugs, a critical public health care goal and a priority for the agency.

25 Sep 2012

Lonafarnib proves effective for children with progeria

Results of the first-ever clinical drug trial for children with Progeria, a rare, fatal "rapid-aging" disease, demonstrate the efficacy of a farnesyltransferase inhibitor (FTI), a drug originally developed to treat cancer. The clinical trial results, completed only six years after scientists identified the cause of Progeria, included significant improvements in weight gain, bone structure and, most importantly, the cardiovascular system, according to The Progeria Research Foundation (PRF) and Boston Children's Hospital.

25 Sep 2012

Mailed sun protection kits lead to higher frequency of sun protective behaviors

A blistering sunburn during childhood or adolescence more than doubles the adult risk of skin cancer. The accumulation of long-term sun exposure may be equally dangerous.

24 Sep 2012

Study to examine SYMPLICITY renal denervation system for treatment-resistant hypertension

The University of Michigan Cardiovascular Center will participate in a national clinical trial to treat the most challenging form of high blood pressure.

24 Sep 2012

Ohr commences Phase II clinical trial of Squalamine for wet-AMD

Ohr Pharmaceutical today announced the initiation of a Phase II clinical trial to evaluate the efficacy and safety of Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration.

24 Sep 2012

Sanofi chooses OnPoint clinical trial management system from BioClinica

BioClinica, Inc., a global provider of clinical trial management services, announced today that Sanofi, one of the world's largest pharmaceutical companies, has selected BioClinica's OnPoint as the company's standard CTMS (Clinical Trial Management System).

From Clario 24 Sep 2012

Improvements in trauma care are urgently needed

With traumatic injuries claiming almost six million lives a year, improvements in care, including in the challenging areas of brain and bone injuries, and haemorrhage, are urgently needed.

24 Sep 2012

Even partially matched bone marrow transplants can eliminate sickle cell disease in some patients

In a preliminary clinical trial, investigators at Johns Hopkins have shown that even partially matched bone marrow transplants can eliminate sickle cell disease in some patients, ridding them of painful and debilitating symptoms and the need for a lifetime of pain medications and blood transfusions.

24 Sep 2012

Boehringer Ingelheim completes enrollment in nintedanib Phase III trials for IPF

Boehringer Ingelheim is pleased to announce the last patients have been randomised into the Phase III sister trials assessing the efficacy and safety of nintedanib (150 mg twice daily) in patients with idiopathic pulmonary fibrosis (IPF).

24 Sep 2012

Partially-matched bone marrow transplants can eliminate sickle cell disease in some patients

In a preliminary clinical trial, investigators at Johns Hopkins have shown that even partially-matched bone marrow transplants can eliminate sickle cell disease in some patients, ridding them of painful and debilitating symptoms, and the need for a lifetime of pain medications and blood transfusions. The researchers say the use of such marrow could potentially help make bone marrow transplants accessible to a majority of sickle cell patients who need them.

21 Sep 2012

EMA CHMP adopts positive opinion for ELIQUIS to prevent stroke, systemic embolism in NVAF patients

Bristol-Myers Squibb and Pfizer Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending that ELIQUIS (apixaban) be granted approval for the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) and one or more risk factors for stroke.

21 Sep 2012

Simultaneous computer brain exercises and electromagnetic stimulation for Alzheimer's disease treatment

World Alzheimer's Day - As the planet turns its attention to World Alzheimer's Day, an emerging technology using focused computer brain exercises may offer new hope to Alzheimer's patients and their families.

21 Sep 2012

Partially-matched bone marrow transplants can eliminate sickle cell disease in some patients

21 Sep 2012

Investigators identify two promising therapies to treat patients with acute megakaryocytic leukemia

Investigators at Northwestern University Feinberg School of Medicine have identified two promising therapies to treat patients with acute megakaryocytic leukemia (AMKL), a rare form of leukemia where the number of cases is expected to increase with the aging population.

21 Sep 2012

MD Anderson introduces Moon Shots Program to reduce cancer deaths

The University of Texas MD Anderson Cancer Center announces the launch of the Moon Shots Program, an unprecedented effort to dramatically accelerate the pace of converting scientific discoveries into clinical advances that reduce cancer deaths.

21 Sep 2012

ChromaDex announces findings from pTeroPure Phase 2/3 trial on high blood pressure

ChromaDex Corporation announced today findings from a Phase 2/3 trial at the University of Mississippi Medical Center showing its patented nutritional ingredient pTeroPure (pterostilbene) significantly reduced blood pressure in adults.

21 Sep 2012

Boehringer Ingelheim files MAA with EMA for afatinib approval

Today, Boehringer Ingelheim has announced the submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) for approval of afatinib, the first irreversible ErbB Family Blocker, as a treatment for patients with EGFR (ErbB1) mutation positive non-small cell lung cancer (NSCLC). Afatinib has demonstrated unprecedented efficacy versus chemotherapy in the Phase III LUX-Lung 3 registration trial, which provides pivotal support for this submission.

20 Sep 2012

Enrollment complete in Gamida Cell’s NiCord Phase I/II trial for hematological malignancies

Gamida Cell, a leader in adult stem cell expansion technologies and products, announced today that it has completed enrollment for a Phase I/II clinical trial of NiCord, the company's second pipeline product.

20 Sep 2012

Navidea commences enrollment in [18F]NAV4694 Phase 2 study for Alzheimer's

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that enrollment has commenced at two sites participating in its Phase 2, open-label, safety and efficacy PET imaging study of [18F]NAV4694 for detection of cerebral β-amyloid plaque in subjects diagnosed with probable Alzheimer's disease (AD).

19 Sep 2012

Tranexamic acid: an interview with Prof Ian Roberts

Tranexamic acid is a medicine that reduces blood clot breakdown. In this way it helps in patients with bleeding.

19 Sep 2012

Clinical Trial News and Research

FDA forms new internal task force to support development of new antibacterial drugs

Lonafarnib proves effective for children with progeria

Mailed sun protection kits lead to higher frequency of sun protective behaviors

Study to examine SYMPLICITY renal denervation system for treatment-resistant hypertension

Ohr commences Phase II clinical trial of Squalamine for wet-AMD

Sanofi chooses OnPoint clinical trial management system from BioClinica

Improvements in trauma care are urgently needed

Even partially matched bone marrow transplants can eliminate sickle cell disease in some patients

Boehringer Ingelheim completes enrollment in nintedanib Phase III trials for IPF

Partially-matched bone marrow transplants can eliminate sickle cell disease in some patients

EMA CHMP adopts positive opinion for ELIQUIS to prevent stroke, systemic embolism in NVAF patients

Simultaneous computer brain exercises and electromagnetic stimulation for Alzheimer's disease treatment

Partially-matched bone marrow transplants can eliminate sickle cell disease in some patients

Investigators identify two promising therapies to treat patients with acute megakaryocytic leukemia

MD Anderson introduces Moon Shots Program to reduce cancer deaths

ChromaDex announces findings from pTeroPure Phase 2/3 trial on high blood pressure

Boehringer Ingelheim files MAA with EMA for afatinib approval

Enrollment complete in Gamida Cell’s NiCord Phase I/II trial for hematological malignancies

Navidea commences enrollment in [18F]NAV4694 Phase 2 study for Alzheimer's

Tranexamic acid: an interview with Prof Ian Roberts

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer